As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback